TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33788326
Drug: Complete harm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete harm reduction program (HRP) participation (≥ 60 mg/day methadone and 100% needle and syringe program coverage)
Study: 33788326
Drug: No HRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No HRP and partial HRP participation (< 60 mg/day methadone and/or < 100% NSP coverage)
Study: 32381925
Drug: L-carnitine oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine oral supplements (group C)
Study: 32381925
Drug: No L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No L-carnitine oral supplements (group N)
Study: 36384737
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg once daily for 10 days
Study: 36409058
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (1 g/d) as an add-on to lithium carbonate
Study: 33301740
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (5 × 5 Gy over a maximum of 8 days) followed by six cycles of CAPOX chemotherapy or nine cycles of FOLFOX4, followed by total mesorectal excision.
Study: 33301740
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care: 28 daily fractions of 1.8 Gy up to 50.4 Gy or 25 fractions of 2.0 Gy up to 50.0 Gy with concomitant capecitabine 825 mg/m2, followed by total mesorectal excision and optional adjuvant chemotherapy.
Study: 34254189
Drug: Insoluble oat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insoluble oat hulls fibre supplement
Study: 32532035
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs enriched hen eggs (1053 mg n-3 PUFAs/day)
Study: 32532035
Drug: Regular hen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular hen eggs (249 mg n-3 PUFAs/day)
Study: 36069928
Drug: Current diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current diabetes care (insulin pump or pen therapy)
Study: 33963722
Drug: 0.2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg · kg‐1·h‐1 DEX
Study: 33963722
Drug: 0.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg · kg‐1·h‐1 DEX
Study: 33963722
Drug: 0.8 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 μg · kg‐1·h‐1 DEX
Study: 33025006
Drug: Warm rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm rice (14 mg · kg‐1 · d‐1)
Study: 33025006
Drug: Cold rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold rice (14 mg · kg‐1 · d‐1)
Study: 32758058
Drug: Leucine (1.11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine (1.11 g) + Resveratrol (50 mg)
Study: 33303111
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (in thrombophilia subgroup)
Study: 35587070
Drug: N-acetylcysteine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine and propolis (NACp) 600 mg
Study: 35587070
Drug: N-acetylcysteine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine and propolis (NACp) 1200 mg
Study: 33848070
Drug: Parasacral TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parasacral TENS administered twice weekly
Study: 33848070
Drug: Parasacral TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parasacral TENS administered three times weekly
Study: 33019888
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (direct usual care aphasia therapy)
Study: 33019888
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity group (usual care-plus or prescribed direct aphasia therapy)
Study: 33771104
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy plus guideline directed therapy (BAT + GDT)
Study: 33771104
Drug: Guideline directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline directed therapy (GDT) alone
Study: 32975045
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) treatment
Study: 35370914
Drug: Optimized acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized acupuncture and moxibustion treatment (OAMT), given five times per week for 4 weeks.
Study: 36329513
Drug: Treamid 50
Normalized name: Treamid
DrugBank: Treamid (DB16365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treamid 50 mg once a day for 4 weeks
Study: 32927285
Drug: Apomorphine sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingual film (APL) titration (10–35 mg)
Study: 35068168
Drug: Apomorphine sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingual film (APL)
Study: 37578800
Drug: Immediate-release carbidopa-levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbidopa-levodopa
Study: 36279409
Drug: Norepinephrine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine at a starting rate of 0.05 μg·kg‐1·min‐1 (n = 62)
Study: 36279409
Drug: Phenylephrine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine at a starting rate of 0.5 μg·kg‐1·min‐1 (n = 62)
Study: 33646860
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester (KE) supplement (600 mg/kg body mass)
Study: 33128085
Drug: Immunohistochemical panel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical panel (eight antibodies)
Study: 38868491
Drug: Trauma-Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Study: 32920022
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of enteric-coated aspirin daily
Study: 33907782
Drug: Multi-dimensional oral
Normalized name: Finafta Multi Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dimensional oral cleaning intervention model
Study: 35590291
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral health education (Control)
Study: 33388951
Drug: Glasdegib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib (100 mg, oral, fasted conditions)
Study: 34183579
Drug: Probiotic (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (Lactobacillus rhamnosus GG and a combination probiotic: L. rhamnosus and L. helveticus)
Study: 33765581
Drug: EAE food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAE food supplement (500 mg daily for 6 months)
Study: 34529781
Drug: Protocol-driven intensified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-driven intensified diuretic therapies (n = 43)
Study: 34529781
Drug: Diuretic-induced natriuresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic-induced natriuresis
Study: 34529781
Drug: Pre-diuretic urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-diuretic urine sodium to creatinine ratio
Study: 35113639
Drug: Emotion-Focused Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion-Focused Therapy (EFT)
Study: 33971933
Drug: Add‐Aspirin trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add‐Aspirin trial with EHR data from NCRAS
Study: 33971933
Drug: PATCH trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATCH trial with EHR data from NICOR
Study: 33971933
Drug: PATCH trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATCH trial with EHR data from NHS Digital
Study: 39215959
Drug: Clopidogrel monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel monotherapy
Study: 35365511
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (open reduction and internal fixation)
Study: 35365511
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (closed reduction followed by cast treatment)
Study: 33236211
Drug: Decongestive lymphatic
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestive lymphatic treatment (DLT) consisting of an intensive treatment phase of 3 weeks, followed by a maintenance treatment phase of 6 months.
Study: 34105695
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNT‐A) injections
Study: 34422049
Drug: Apatinib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib combined with chemotherapy
Study: 34058423
Drug: Prophylactic negative-pressure
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic negative-pressure wound therapy device
Study: 35312891
Drug: Tablet-based patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based patient education tool
Study: 32338345
Drug: Single-dose apalutamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose apalutamide 240 mg
Study: 35317414
Drug: SQ‐LNS (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ‐LNS (130 µg selenium/20 g)
Study: 35317414
Drug: MMN (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMN (130 µg selenium per capsule)
Study: 32771032
Drug: Hydroxychloroquine Phosphate/Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a day for 5 days)
Study: 35799756
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg orally twice a day for 5 days)
Study: 35799756
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2‐5)
Study: 32771032
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Hydroxychloroquine and Oseltamivir
Study: 32771032
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Hydroxychloroquine and Azithromycin
Study: 32771032
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Oseltamivir and Azithromycin
Study: 32771032
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug regimen (Hydroxychloroquine, Oseltamivir, and Azithromycin)
Study: 34528576
Drug: Rucaparib (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib (maintenance therapy)
Study: 33372679
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d resveratrol
Study: 33423824
Drug: Diazepam (DZP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (DZP), doses 5–20 mg IV
Study: 33423824
Drug: Dexmedetomidine (DEX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (DEX), infusion 2–7 mcg/kg/min
Study: 34313843
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen 1 g
Study: 36017782
Drug: Multiple-day dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multiple-day dexamethasone (DEX) plus palonosetron and NK-1 receptor antagonists (NK-1RAs)
Study: 35660990
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg/day
Study: 35660990
Drug: Clonazepam 1
Normalized name: clonazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 1 mg/day
Study: 35660990
Drug: Trazodone 50
Normalized name: traZODone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 50 mg/day
Study: 32720618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previous hypoglycemic therapy)
Study: 36145177
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg choline/d
Study: 38386178
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg every 4 weeks (Q4W)
Study: 33568556
Drug: guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: guselkumab 100 mg at Week0, Week4, then Q8W
Study: 32501276
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (improved treatment as usual - iTAU)
Study: 33871218
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg/day for 12 weeks)
Study: 34251458
Drug: Total FORTA
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total FORTA and potentially inappropriate medication score
Study: 34251458
Drug: Men and
Normalized name: MINOXIDIL 2 g in 100 mL TOPICAL SOLUTION [Loesch Hair Regrowth Formula Unscented Topical Solution Regular-Strength for Men and Women]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men and rectal cancer patients
Study: 32007513
Drug: Serlopitant 5
Normalized name: Serlopitant
DrugBank: Serlopitant (DB12973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serlopitant 5 mg daily for 8 weeks
Study: 32553790
Drug: Combination postoperative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination postoperative radiotherapy (PORT) and androgen deprivation therapy (ADT)
Study: 34479619
Drug: Anyu Peibo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anyu Peibo Capsule (1.6 g per day for 8 weeks)
Study: 35819570
Drug: macitentan 10
Normalized name: macitentan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: macitentan 10 mg
Study: 32182387
Drug: Topical ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketoconazole 2% cream twice daily and placebo (GI)
Study: 32182387
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% adapalene gel twice daily and placebo (GII)
Study: 32182387
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination of 0.1% adapalene gel (at night) and ketoconazole 2% cream (in the morning) (GIII)
Study: 35015037
Drug: Once-weekly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous semaglutide, 2.4 mg
Study: 35015037
Drug: Once-daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily subcutaneous liraglutide, 3.0 mg
Study: 32556276
Drug: Antiparasitic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparasitic treatment (specifics not provided)
Study: 32556276
Drug: Mild antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild antibody response
Study: 32556276
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose albendazole regime
Study: 32556276
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of dexamethasone
Study: 35941584
Drug: Canagliflozin treatment
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Canagliflozin treatment
Study: 34160288
Drug: 20 IU·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU·kg body wt-1 rHuEPO injections every second day for 3 weeks at sea level
Study: 34160288
Drug: Concurrent rHuEPO
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent rHuEPO treatment and altitude exposure
Study: 33210604
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (300 mg)
Study: 33210604
Drug: Magnesium-vitamin B6
Normalized name: magnesium oxide / vitamin B6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-vitamin B6 supplementation (300 mg magnesium + 30 mg vitamin B6)
Study: 32431667
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg/day)
Study: 36242622
Drug: Biodegradable hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable hyaluronic acid microneedle patch (BHMN patch)
Study: 36242622
Drug: Needleless patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needleless patch (NL patch)
Study: 36242622
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (BHMN patch and NL patch)
Study: 34217127
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with 3% lavender oil (2.5 cc, gentle massage for 10 min every night for a month)
Study: 36307315
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic medicines (IHMs)
Study: 32133910
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of L-tyrosine
Study: 32143877
Drug: Threshold inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold inspiratory muscle training (TIMT) at 30% of maximal inspiratory pressure (MIP) for 15 min, twice per day for 8 weeks
Study: 39186921
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events (TEAEs)
Study: 32437507
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks until disease progression, unacceptable toxic effects, or death
Study: 32437507
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg every 2 weeks until disease progression, unacceptable toxic effects, or death
Study: 33846727
Drug: Supplemental soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental soybean meal at 100% of the estimated rumen‐degradable protein requirement (F) provided daily (D)
Study: 33846727
Drug: Supplemental soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental soybean meal at 50% of the estimated rumen‐degradable protein requirement (H) provided daily (D)
Study: 33846727
Drug: All supplements
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All supplements provided
Study: 32854869
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment of SCD
Study: 32854869
Drug: Penicillin, vaccines,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin, vaccines, and hydroxyurea
Study: 34993933
Drug: Eflapegrastim (1.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflapegrastim (1.1, 3.3, 10, 45, 135, and 270 μg/kg)
Study: 38194162
Drug: Pegfilgrastim (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (6 mg)
Study: 32756094
Drug: Pureed rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pureed rice with gelling agent
Study: 32756094
Drug: Pureed rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pureed rice without gelling agent
Study: 32756094
Drug: Older patients
Normalized name: black alder pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older patients (irrespective of gelling agent presence)
Study: 35776835
Drug: Oxycodone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (10 mg)
Study: 33548380
Drug: High-polyphenolic extra
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-polyphenolic extra virgin olive oil (EVOO), 50 mL
Study: 33548380
Drug: Refined olive
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined olive oil without polyphenols, 50 mL
Study: 34107792
Drug: Topical silicone
Normalized name: silicones Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silicone gel only
Study: 616520941
Drug: PI +
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PI + RTV + TVD (multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF)
Study: 36153205
Drug: Voice treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice treatment with Acapella Choice device plus vocal hygiene program
Study: 36153205
Drug: Voice treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice treatment with Water resistance therapy plus vocal hygiene program
Study: 34337965
Drug: Omeprazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (1 mg/kg, PO, q 12 h)
Study: 34337965
Drug: Famotidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (1 mg/kg, PO, q 12 h)
Study: 37280508
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) oxygen therapy
Study: 32423462
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion (EI) of β-lactam antibiotics (BLA)
Study: 32423462
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (II) of β-lactam antibiotics (BLA)
Study: 32712762
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg kg−1 bolus followed by 10 mcg kg−1 min−1 infusion
Study: 32712762
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg kg−1 bolus followed by 5 mcg kg−1 min−1 infusion
Study: 32702911
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with electroacupuncture (EA) and computerized cognitive rehabilitation treatment (CCRT)